Advertisement

Surgical and radiosurgical treatment strategies for Cushing’s disease

  • Adomas Bunevicius
  • Edward R. Laws
  • Mary Lee Vance
  • Sherry Iuliano
  • Jason SheehanEmail author
Topic Review

Abstract

Introduction

Cushing’s disease (CD) is rare disorder that should be adequately managed to optimize long-term prognosis. Treatment of CD is multidisciplinary and often includes surgical resection, adjuvant stereotactic radiosurgery (SRS), and medical treatment. Here we review surgical and radiosurgical treatment strategies for ACTH producing pituitary adenomas.

Methods

A comprehensive literature review was carried out to review remission and recurrence rates, and complications of surgical and SRS treatments of ACTH producing pituitary adenomas.

Results

Surgical resection plays a central role in the management of ACTH secreting pituitary adenomas and usually allows rapid endocrine remission that ranges from 69 to 90%. The most common complications after resection include some degree of new hypopituitarism, diabetes insipidus and CSF leak. Devastating complications, such as injury of vascular and neural structures, are very rare. Surgeon experience and adequate pre-operative imaging are important for safe and successful surgery. Endocrine recurrence rates after resection range from 9 to 30%. SRS is often employed for incompletely resected adenomas. Endocrine remission after SRS ranges from 35 to 72%. The most common complication of SRS is new anterior pituitary gland deficiency. Recurrence rates after GKRS range from 18 to 24%.

Conclusions

Transsphenoidal resection of ACTH producing pituitary adenoma is a safe and highly effective procedure for CD in experienced hands. Radiosurgery is more frequently used as treatment of residual and recurrent adenoma and persistent CD. Long-term endocrine and imaging follow-up is important as delayed recurrences and hypopituitarism are not infrequent.

Keywords

Cushing’s disease Pituitary adenoma Surgery Radiosurgery Gamma knife 

Notes

Compliance with ethical standards

Conflict of interest

All authors report no conflicts of interest.

References

  1. 1.
    Cushing H (1932) The basophil adenomas of the pituitary body and their clinical manifestations (Pituitary Basophilism). Obes Res 2:486–508CrossRefGoogle Scholar
  2. 2.
    Lindholm J, Juul S, Jørgensen JO et al (2001) Incidence and late prognosis of cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86:117–123.  https://doi.org/10.1210/jcem.86.1.7093 CrossRefPubMedGoogle Scholar
  3. 3.
    Ragnarsson O, Olsson DS, Chantzichristos D et al (2019) The incidence of Cushing’s disease: a nationwide Swedish study. Pituitary 22:179–186.  https://doi.org/10.1007/s11102-019-00951-1 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Broder MS, Neary MP, Chang E et al (2015) Incidence of Cushing’s syndrome and Cushing’s disease in commercially-insured patients %3c65 years old in the United States. Pituitary 18:283–289.  https://doi.org/10.1007/s11102-014-0569-6 CrossRefPubMedGoogle Scholar
  5. 5.
    Catargi B, Rigalleau V, Poussin A et al (2003) Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab 88:5808–5813.  https://doi.org/10.1210/jc.2003-030254 CrossRefPubMedGoogle Scholar
  6. 6.
    Leibowitz G, Tsur A, Chayen SD et al (1996) Pre-clinical Cushing’s syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf) 44:717–722CrossRefGoogle Scholar
  7. 7.
    Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. The Lancet 367:1605–1617.  https://doi.org/10.1016/S0140-6736(06)68699-6 CrossRefGoogle Scholar
  8. 8.
    Isidori AM, Kaltsas GA, Pozza C et al (2006) The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 91:371–377.  https://doi.org/10.1210/jc.2005-1542 CrossRefPubMedGoogle Scholar
  9. 9.
    Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing’s syndrome. The Lancet 386:913–927.  https://doi.org/10.1016/S0140-6736(14)61375-1 CrossRefGoogle Scholar
  10. 10.
    Sharma ST, Nieman LK, Feelders RA (2015) Comorbidities in Cushing’s disease. Pituitary 18:188–194.  https://doi.org/10.1007/s11102-015-0645-6 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Clayton RN, Jones PW, Reulen RC et al (2016) Mortality in patients with Cushing’s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 4:569–576.  https://doi.org/10.1016/S2213-8587(16)30005-5 CrossRefPubMedGoogle Scholar
  12. 12.
    Nieman LK, Biller BMK, Findling JW et al (2015) Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline summary of recommendations. J Clin Endocrinol Metab 100:2807–2831.  https://doi.org/10.1210/jc.2015-1818 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Graversen D, Vestergaard P, Stochholm K et al (2012) Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur J Intern Med 23:278–282.  https://doi.org/10.1016/j.ejim.2011.10.013 CrossRefPubMedGoogle Scholar
  14. 14.
    Broersen LHA, Andela CD, Dekkers OM et al (2019) Improvement but no normalization of quality of life and cognitive functioning after treatment for Cushing’s syndrome. J Clin Endocrinol Metab.  https://doi.org/10.1210/jc.2019-01054 CrossRefPubMedGoogle Scholar
  15. 15.
    Jiang H, Ren J, He N-Y et al (2017) Volumetric magnetic resonance imaging analysis in patients with short-term remission of Cushing’s disease. Clin Endocrinol (Oxf) 87:367–374.  https://doi.org/10.1111/cen.13381 CrossRefGoogle Scholar
  16. 16.
    Petersenn S, Beckers A, Ferone D et al (2015) Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol 172:R227–239.  https://doi.org/10.1530/EJE-14-0883 CrossRefPubMedGoogle Scholar
  17. 17.
    Pendharkar AV, Sussman ES, Ho AL et al (2015) Cushing’s disease: predicting long-term remission after surgical treatment. Neurosurg Focus 38:E13.  https://doi.org/10.3171/2014.10.FOCUS14682 CrossRefPubMedGoogle Scholar
  18. 18.
    Aghi MK (2008) Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab 4:560–568.  https://doi.org/10.1038/ncpendmet0947 CrossRefPubMedGoogle Scholar
  19. 19.
    Liu JK, Fleseriu M, Delashaw JB et al (2007) Treatment options for Cushing disease after unsuccessful transsphenoidal surgery. Neurosurg Focus 23:E8.  https://doi.org/10.3171/foc.2007.23.3.10 CrossRefPubMedGoogle Scholar
  20. 20.
    Patil CG, Veeravagu A, Prevedello DM et al (2008) Outcomes after repeat transsphenoidal surgery for recurrent Cushing’s disease. Neurosurgery 63:266–270.  https://doi.org/10.1227/01.NEU.0000313117.35824.9F (discussion 270–271)CrossRefPubMedGoogle Scholar
  21. 21.
    Molitch ME (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA 317:516–524.  https://doi.org/10.1001/jama.2016.19699 CrossRefPubMedGoogle Scholar
  22. 22.
    Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing’s disease. Endocr Rev 36:385–486.  https://doi.org/10.1210/er.2013-1048 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Patel J, Eloy JA, Liu JK (2015) Nelson’s syndrome: a review of the clinical manifestations, pathophysiology, and treatment strategies. Neurosurg Focus 38:E14.  https://doi.org/10.3171/2014.10.FOCUS14681 CrossRefPubMedGoogle Scholar
  24. 24.
    Hardy J (1969) Transsphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg 16:185–217CrossRefGoogle Scholar
  25. 25.
    Bashari WA, Senanayake R, Fernández-Pombo A et al (2019) Modern imaging of pituitary adenomas. Best Pract Res Clin Endocrinol Metab.  https://doi.org/10.1016/j.beem.2019.05.002 CrossRefPubMedGoogle Scholar
  26. 26.
    Lüdecke DK, Flitsch J, Knappe UJ, Saeger W (2001) Cushing’s disease: a surgical view. J Neurooncol 54:151–166CrossRefGoogle Scholar
  27. 27.
    Salenave S, Gatta B, Pecheur S et al (2004) Pituitary magnetic resonance imaging findings do not influence surgical outcome in adrenocorticotropin-secreting microadenomas. J Clin Endocrinol Metab 89:3371–3376.  https://doi.org/10.1210/jc.2003-031908 CrossRefPubMedGoogle Scholar
  28. 28.
    de Rotte AAJ, Groenewegen A, Rutgers DR et al (2016) High resolution pituitary gland MRI at 7.0 tesla: a clinical evaluation in Cushing’s disease. Eur Radiol 26:271–277.  https://doi.org/10.1007/s00330-015-3809-x CrossRefPubMedGoogle Scholar
  29. 29.
    Lonser RR, Ksendzovsky A, Wind JJ et al (2012) Prospective evaluation of the characteristics and incidence of adenoma-associated dural invasion in Cushing disease. J Neurosurg 116:272–279.  https://doi.org/10.3171/2011.8.JNS11456 CrossRefPubMedGoogle Scholar
  30. 30.
    Meij BP, Lopes M-BS, Ellegala DB et al (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96:195–208.  https://doi.org/10.3171/jns.2002.96.2.0195 CrossRefPubMedGoogle Scholar
  31. 31.
    Oldfield EH (2017) Cushing’s disease: lessons learned from 1500 cases. Neurosurgery 64:27–36.  https://doi.org/10.1093/neuros/nyx378 CrossRefPubMedGoogle Scholar
  32. 32.
    Selman WR, Laws ER, Scheithauer BW, Carpenter SM (1986) The occurrence of dural invasion in pituitary adenomas. J Neurosurg 64:402–407.  https://doi.org/10.3171/jns.1986.64.3.0402 CrossRefPubMedGoogle Scholar
  33. 33.
    Cottier J-P, Destrieux C, Brunereau L et al (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215:463–469.  https://doi.org/10.1148/radiology.215.2.r00ap18463 CrossRefPubMedGoogle Scholar
  34. 34.
    Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus spacea magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–618.  https://doi.org/10.1097/00006123-199310000-00008 CrossRefPubMedGoogle Scholar
  35. 35.
    Niu J, Zhang S, Ma S et al (2019) Preoperative prediction of cavernous sinus invasion by pituitary adenomas using a radiomics method based on magnetic resonance images. Eur Radiol 29:1625–1634.  https://doi.org/10.1007/s00330-018-5725-3 CrossRefPubMedGoogle Scholar
  36. 36.
    Honegger J, Grimm F (2018) The experience with transsphenoidal surgery and its importance to outcomes. Pituitary 21:545–555.  https://doi.org/10.1007/s11102-018-0904-4 CrossRefPubMedGoogle Scholar
  37. 37.
    Barker FG, Klibanski A, Swearingen B (2003) Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 88:4709–4719.  https://doi.org/10.1210/jc.2003-030461 CrossRefPubMedGoogle Scholar
  38. 38.
    Hofmann BM, Hlavac M, Martinez R et al (2008) Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 108:9–18.  https://doi.org/10.3171/JNS/2008/108/01/0009 CrossRefPubMedGoogle Scholar
  39. 39.
    Martínez Ortega AJ, Venegas-Moreno E, Dios E et al (2019) Surgical outcomes and comorbidities in cushing disease: 30 years of experience in a referral center. World Neurosurg 122:e436–e442.  https://doi.org/10.1016/j.wneu.2018.10.067 CrossRefPubMedGoogle Scholar
  40. 40.
    Asuzu D, Chatain GP, Hayes C et al (2017) Normalized early postoperative cortisol and ACTH values predict nonremission after surgery for Cushing disease. J Clin Endocrinol Metab 102:2179–2187.  https://doi.org/10.1210/jc.2016-3908 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Starke RM, Reames DL, Chen C-J et al (2013) Endoscopic transsphenoidal surgery for cushing disease: techniques, outcomes, and predictors of remission. Neurosurgery 72:240–247.  https://doi.org/10.1227/NEU.0b013e31827b966a (discussion 247)CrossRefPubMedGoogle Scholar
  42. 42.
    Valassi E, Biller BMK, Swearingen B et al (2010) Delayed remission after transsphenoidal surgery in patients with Cushing’s disease. J Clin Endocrinol Metab 95:601–610.  https://doi.org/10.1210/jc.2009-1672 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Hassan-Smith ZK, Sherlock M, Reulen RC et al (2012) Outcome of Cushing’s disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab 97:1194–1201.  https://doi.org/10.1210/jc.2011-2957 CrossRefPubMedGoogle Scholar
  44. 44.
    Woodmansee WW, Carmichael J, Kelly D, Katznelson L (2015) American association of clinical endocrinologists and american college of endocrinology disease state clinical review: postoperative management following pituitary surgery. Endocr Pract 21:832–838.  https://doi.org/10.4158/EP14541.DSCR CrossRefPubMedGoogle Scholar
  45. 45.
    Hammer GD, Tyrrell JB, Lamborn KR et al (2004) Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J Clin Endocrinol Metab 89:6348–6357.  https://doi.org/10.1210/jc.2003-032180 CrossRefPubMedGoogle Scholar
  46. 46.
    Ciric I, Ragin A, Baumgartner C, Pierce D (1997) Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 40:225–236.  https://doi.org/10.1097/00006123-199702000-00001 (discussion 236–237)CrossRefPubMedGoogle Scholar
  47. 47.
    Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15:71–83.  https://doi.org/10.1007/s11102-011-0347-7 CrossRefPubMedGoogle Scholar
  48. 48.
    Staartjes VE, Zattra CM, Akeret K et al (2019) Neural network-based identification of patients at high risk for intraoperative cerebrospinal fluid leaks in endoscopic pituitary surgery. J Neurosurg.  https://doi.org/10.3171/2019.4.JNS19477 CrossRefPubMedGoogle Scholar
  49. 49.
    Keskin FE, Ozkaya HM, Bolayirli M et al (2017) Outcomes of primary transsphenoidal surgery in Cushing disease: experience of a tertiary center. World Neurosurg 106:374–381.  https://doi.org/10.1016/j.wneu.2017.07.014 CrossRefPubMedGoogle Scholar
  50. 50.
    Gupta A, Xu Z, Kano H et al (2018) Upfront Gamma Knife radiosurgery for Cushing’s disease and acromegaly: a multicenter, international study. J Neurosurg.  https://doi.org/10.3171/2018.3.JNS18110 CrossRefPubMedGoogle Scholar
  51. 51.
    Garcia-Barros M, Paris F, Cordon-Cardo C et al (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155–1159.  https://doi.org/10.1126/science.1082504 CrossRefGoogle Scholar
  52. 52.
    Mehta GU, Ding D, Patibandla MR et al (2017) Stereotactic radiosurgery for Cushing disease: results of an international, multicenter study. J Clin Endocrinol Metab 102:4284–4291.  https://doi.org/10.1210/jc.2017-01385 CrossRefPubMedGoogle Scholar
  53. 53.
    Wattson DA, Tanguturi SK, Spiegel DY et al (2014) Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys 90:532–539.  https://doi.org/10.1016/j.ijrobp.2014.06.068 CrossRefPubMedGoogle Scholar
  54. 54.
    Castinetti F, Nagai M, Morange I et al (2009) Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 94:3400–3407.  https://doi.org/10.1210/jc.2008-2772 CrossRefPubMedGoogle Scholar
  55. 55.
    Kobayashi T, Kida Y, Mori Y (2002) Gamma knife radiosurgery in the treatment of Cushing disease: long-term results. J Neurosurg 97:422–428.  https://doi.org/10.3171/jns.2002.97.supplement CrossRefPubMedGoogle Scholar
  56. 56.
    Hughes JD, Young WF, Chang AY et al (2019) Radiosurgical management of patients with persistent or recurrent cushing disease after prior transsphenoidal surgery: a management algorithm based on a 25-year experience. Neurosurgery.  https://doi.org/10.1093/neuros/nyz159 CrossRefPubMedGoogle Scholar
  57. 57.
    Voges J, Kocher M, Runge M et al (2006) Linear accelerator radiosurgery for pituitary macroadenomas. Cancer 107:1355–1364.  https://doi.org/10.1002/cncr.22128 CrossRefPubMedGoogle Scholar
  58. 58.
    Wein L, Dally M, Bach LA (2012) Stereotactic radiosurgery for treatment of Cushing disease: an Australian experience. Internal Medicine Journal 42:1153–1156.  https://doi.org/10.1111/j.1445-5994.2012.02903.x CrossRefPubMedGoogle Scholar
  59. 59.
    Wilson PJ, Williams JR, Smee RI (2014) Cushing’s disease: a single centre’s experience using the linear accelerator (LINAC) for stereotactic radiosurgery and fractionated stereotactic radiotherapy. J Clin Neurosci 21:100–106.  https://doi.org/10.1016/j.jocn.2013.04.007 CrossRefPubMedGoogle Scholar
  60. 60.
    Moore JM, Sala E, Amorin A et al (2018) CyberKnife radiosurgery in the multimodal management of patients with Cushing disease. World Neurosurg 112:e425–e430.  https://doi.org/10.1016/j.wneu.2018.01.057 CrossRefPubMedGoogle Scholar
  61. 61.
    Shrivastava A, Mohammed N, Xu Z et al (2019) Outcomes after Gamma Knife stereotactic radiosurgery in pediatric patients with Cushing disease or acromegaly: a multi-institutional study. World Neurosurg.  https://doi.org/10.1016/j.wneu.2019.01.252 CrossRefPubMedGoogle Scholar
  62. 62.
    Devin JK, Allen GS, Cmelak AJ et al (2004) The efficacy of linear accelerator radiosurgery in the management of patients with Cushing’s disease. SFN 82:254–262.  https://doi.org/10.1159/000083476 CrossRefGoogle Scholar
  63. 63.
    Wolf A, Naylor K, Tam M et al (2019) Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study. Lancet Oncol 20:159–164.  https://doi.org/10.1016/S1470-2045(18)30659-4 CrossRefPubMedGoogle Scholar
  64. 64.
    Tooze A, Sheehan JP (2018) Neurocognitive changes in pituitary adenoma patients after Gamma Knife radiosurgery. J Neurosurg 129:55–62.  https://doi.org/10.3171/2018.7.GKS181595 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurosurgeryUniversity of VirginiaCharlottesvilleUSA
  2. 2.Department of Neurosurgery, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  3. 3.Department of MedicineUniversity of Virginia Health SystemCharlottesvilleUSA
  4. 4.University of Virginia Health SystemCharlottesvilleUSA

Personalised recommendations